Enhancer	O
-	O
targeted	O
genome	O
editing	O
selectively	O
blocks	O
innate	O
resistance	O
to	O
oncokinase	O
inhibition	O
.	O


Thousands	O
of	O
putative	O
enhancers	O
are	O
characterized	O
in	O
the	O
human	O
genome	O
,	O
yet	O
few	O
have	O
been	O
shown	O
to	O
have	O
a	O
functional	O
role	O
in	O
cancer	O
progression	O
.	O


Inhibiting	O
oncokinases	O
,	O
such	O
as	O
EGFR	O
,	O
ALK	O
,	O
ERBB2	O
,	O
and	O
BRAF	O
,	O
is	O
a	O
mainstay	O
of	O
current	O
cancer	O
therapy	O
but	O
is	O
hindered	O
by	O
innate	O
drug	O
resistance	O
mediated	O
by	O
up	O
-	O
regulation	O
of	O
the	O
HGF	O
receptor	O
,	O
MET	O
.	O


The	O
mechanisms	O
mediating	O
such	O
genomic	O
responses	O
to	O
targeted	O
therapy	O
are	O
unknown	O
.	O


Here	O
,	O
we	O
identify	O
lineage	O
-	O
specific	O
enhancers	O
at	O
the	O
MET	O
locus	O
for	O
multiple	O
common	O
tumor	O
types	O
,	O
including	O
a	O
melanoma	O
lineage	O
-	O
specific	O
enhancer	O
63	O
kb	O
downstream	O
from	O
the	O
MET	O
TSS	O
.	O


This	O
enhancer	O
displays	O
inducible	O
chromatin	O
looping	O
with	O
the	O
MET	B-PROMOTER
promoter	E-PROMOTER
to	O
up	O
-	O
regulate	O
MET	O
expression	O
upon	O
BRAF	O
inhibition	O
.	O


Epigenomic	O
analysis	O
demonstrated	O
that	O
the	O
melanocyte	O
-	O
specific	O
transcription	O
factor	O
,	O
MITF	O
,	O
mediates	O
this	O
enhancer	O
function	O
.	O


Targeted	O
genomic	O
deletion	O
(	O
<	O
7	O
bp	O
)	O
of	O
the	O
MITF	O
motif	O
within	O
the	O
MET	O
enhancer	O
suppressed	O
inducible	O
chromatin	O
looping	O
and	O
innate	O
drug	O
resistance	O
,	O
while	O
maintaining	O
MITF	O
-	O
dependent	O
,	O
inhibitor	O
-	O
induced	O
melanoma	O
cell	O
differentiation	O
.	O


Epigenomic	O
analysis	O
can	O
thus	O
guide	O
functional	O
disruption	O
of	O
regulatory	O
DNA	O
to	O
decouple	O
pro	O
-	O
and	O
anti	O
-	O
oncogenic	O
functions	O
of	O
a	O
dominant	O
transcription	O
factor	O
and	O
block	O
innate	O
resistance	O
to	O
oncokinase	O
therapy	O
.	O
